Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Depreciation (2020 - 2025)

Historic Accumulated Depreciation for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $7.1 million.

  • Bolt Biotherapeutics' Accumulated Depreciation rose 408.64% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 408.64%. This contributed to the annual value of $7.3 million for FY2024, which is 2652.99% up from last year.
  • Bolt Biotherapeutics' Accumulated Depreciation amounted to $7.1 million in Q3 2025, which was up 408.64% from $6.8 million recorded in Q2 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Accumulated Depreciation peaked at $7.3 million during Q4 2024, and registered a low of $1.5 million during Q1 2021.
  • Its 5-year average for Accumulated Depreciation is $4.6 million, with a median of $4.8 million in 2023.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first soared by 8119.45% in 2021, then soared by 260.95% in 2025.
  • Over the past 5 years, Bolt Biotherapeutics' Accumulated Depreciation (Quarter) stood at $2.2 million in 2021, then surged by 74.39% to $3.9 million in 2022, then surged by 46.92% to $5.8 million in 2023, then grew by 26.53% to $7.3 million in 2024, then decreased by 2.01% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $6.8 million for Q2 2025, and $6.5 million during Q1 2025.